Volume 3, Issue 2, December 2018, Page: 44-56
The Role of Ras Oncogene Mutations in Acute Myeloid Leukemia Patients: A Meta-analysis Based on 2502 Cases
Si Li, Department of Pathology, Kunming Medical University, Kunming, P.R. China
Pengbo Zhang, Medical Faculty, Kunming University of Science and Technology, Kunming, P.R. China
Yong Zhang, Department of Oncology, First Affiliated Hospital of Kunming Medical University, Kunming, P.R. China
Li Wang, Department of Pathology, Yunnan First People’s Hospital, Kunming, P.R. China
Received: Dec. 25, 2018;       Accepted: Jan. 15, 2019;       Published: Feb. 18, 2019
DOI: 10.11648/j.aap.20180302.11      View  320      Downloads  69
Abstract
Background: the ras oncogene mutations frequently occurred in acute myeloid leukemia (AML), but as a prognostic factor remains inconclusive. Methods: The databases of PubMed, Web of Science, EMBASE, and the Cochrane. 22 eligible studies were included this study and analysis was conducted by Comprehensive Meta-Analysis Version 2 software program. All eligible study’s quality assessment refers to the European Lung Cancer Party quality scale. Results: Combined analysis showed that ras oncogene mutation was a poor impact on survival in AML patients (Hazard ratios (HRs): 1.50, 1.19-1.89, p <0.001). Nras gene mutation was a worse survival marker in AML (HR: 1.97, 95% CI: 1.35-2.89, p <0.001) and Kras gene mutations was no significance (HR: 1.32, 95% CI: 0.83-2.09, p =0.24) by stratified analysis. In the analysis of age bracket, adults with ras gene mutation had an unfavorable survival (HR: 1.55, 95% CI: 1.19-2.21, p =0.01) and children harbored ras gene mutation was not significantly with prognosis (HR: 1.22, 95% CI: 0.97-1.53, p =0.09) in AML. Conclusions: This study indicated that AML patients was poor prognosis especially in adult group with ras oncogene mutation, in which Nras mutation, but not Kras mutation involved in guiding survival.
Keywords
Acute Myeloid Leukemia, AML, Ras, Prognostic
To cite this article
Si Li, Pengbo Zhang, Yong Zhang, Li Wang, The Role of Ras Oncogene Mutations in Acute Myeloid Leukemia Patients: A Meta-analysis Based on 2502 Cases, Advances in Applied Physiology. Vol. 3, No. 2, 2018, pp. 44-56. doi: 10.11648/j.aap.20180302.11
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Mamdani H, Santos CD, Konig H: Treatment of Acute Myeloid Leukemia in Elderly Patients-A Therapeutic Dilemma. Journal of the American Medical Directors Association 2016, 17 (7): 581-587.
[2]
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia (Version 2. 2016) [https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf].
[3]
Badar T, Patel KP, Thompson PA, DiNardo C, Takahashi K, Cabrero M, Borthakur G, Cortes J, Konopleva M, Kadia T et al: Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leukemia research 2015, 39 (12): 1367-1374.
[4]
Prada-Arismendy J, Arroyave JC, Rothlisberger S: Molecular biomarkers in acute myeloid leukemia. Blood reviews 2016.
[5]
Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T: Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clinical cancer research : an official journal of the American Association for Cancer Research 2005, 11 (4): 1416-1424.
[6]
Paschka P, Marcucci G, Ruppert AS, Mrozek K, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Vardiman JW, Carroll AJ et al: Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv (16) and t (8; 21): a Cancer and Leukemia Group B Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006, 24 (24): 3904-3911.
[7]
Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kronke J, Bullinger L, Spath D, Kayser S, Zucknick M, Gotze K et al: IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2010, 28 (22): 3636-3643.
[8]
Falini B, Nicoletti I, Martelli MF, Mecucci C: Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 2007, 109 (3): 874-885.
[9]
Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O et al: Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. The New England journal of medicine 2012, 366 (12): 1079-1089.
[10]
Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, Franklin R, McCubrey JA: Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). International journal of oncology 2003, 22 (3): 469-480.
[11]
Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, Haller A, Lothaire P, Meert AP, Noel S et al: The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. British journal of cancer 2005, 92 (1): 131-139.
[12]
Fuccio L, Hassan C, Laterza L, Correale L, Pagano N, Bocus P, Fabbri C, Maimone A, Cennamo V, Repici A et al: The role of K-ras gene mutation analysis in EUS-guided FNA cytology specimens for the differential diagnosis of pancreatic solid masses: a meta-analysis of prospective studies. Gastrointestinal endoscopy 2013, 78 (4): 596-608.
[13]
Esteller M, Gonzalez S, Risques RA, Marcuello E, Mangues R, Germa JR, Herman JG, Capella G, Peinado MA: K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001, 19 (2): 299-304.
[14]
Ward AF, Braun BS, Shannon KM: Targeting oncogenic Ras signaling in hematologic malignancies. Blood 2012, 120 (17): 3397-3406.
[15]
Paschka P, Du J, Schlenk RF, Gaidzik VI, Bullinger L, Corbacioglu A, Spath D, Kayser S, Schlegelberger B, Krauter J et al: Secondary genetic lesions in acute myeloid leukemia with inv (16) or t (16; 16): a study of the German-Austrian AML Study Group (AMLSG). Blood 2013, 121 (1): 170-177.
[16]
Aly RM, El-Sharnoby MR, Hagag AA: Prognostic Significance of NRAS Gene Mutations in Children with Acute Myelogenous Leukemia. Mediterranean journal of hematology and infectious diseases 2011, 3 (1): e2011055.
[17]
Kong X CY, He J, et al. : Study of the relationship between ras gene expression and childhood acute myeloid leukemia. Journal of Clinical Pediatrics 2007, 25 (3): 220-224.
[18]
De Melo MB, Lorand-Metze I, Lima CS, Saad ST, Costa FF: N-ras gene point mutations in Brazilian acute myelogenous leukemia patients correlate with a poor prognosis. Leukemia & lymphoma 1997, 24 (3-4): 309-317.
[19]
Goemans BF, Zwaan CM, Miller M, Zimmermann M, Harlow A, Meshinchi S, Loonen AH, Hahlen K, Reinhardt D, Creutzig U et al: Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2005, 19 (9): 1536-1542.
[20]
Ritter M, Kim TD, Lisske P, Thiede C, Schaich M, Neubauer A: Prognostic significance of N-RAS and K-RAS mutations in 232 patients with acute myeloid leukemia. Haematologica 2004, 89 (11): 1397-1399.
[21]
Meshinchi S, Stirewalt DL, Alonzo TA, Zhang Q, Sweetser DA, Woods WG, Bernstein ID, Arceci RJ, Radich JP: Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood 2003, 102 (4): 1474-1479.
[22]
Zuo Z, Medeiros LJ, Chen Z, Liu D, Bueso-Ramos CE, Luthra R, Wang SA: Acute myeloid leukemia (AML) with erythroid predominance exhibits clinical and molecular characteristics that differ from other types of AML. PloS one 2012, 7 (7): e41485.
[23]
Zebisch A, Wolfler A, Fried I, Wolf O, Lind K, Bodner C, Haller M, Drasche A, Pirkebner D, Matallanas D et al: Frequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemia. Leukemia 2012, 26 (8): 1842-1849.
[24]
Preston R, Dabritz J, Hanfler J, Oettle H: Mutational analysis of K-ras codon 12 in blood samples of patients with acute myeloid leukemia. Leukemia research 2010, 34 (7): 883-891.
[25]
Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, Meert AP, Vallot F, Lafitte JJ, Sculier JP: Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. The European respiratory journal 2001, 18 (4): 705-719.
[26]
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8: 16.
[27]
Duval S, Tweedie R: Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000, 56 (2): 455-463.
[28]
Parmar MK, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in medicine 1998, 17 (24): 2815-2834.
[29]
Rosner B, Grove D: Use of the Mann-Whitney U-test for clustered data. Statistics in medicine 1999, 18 (11): 1387-1400.
[30]
Bowden J, Tierney JF, Copas AJ, Burdett S: Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC medical research methodology 2011, 11: 41.
[31]
Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. Bmj 1997, 315 (7109): 629-634.
[32]
Reuter CWM, Krauter J, Onono FO, Bunke T, Damm F, Thol F, Wagner K, Göhring G, Schlegelberger B, Heuser M et al: Lack of noncanonical RAS mutations in cytogenetically normal acute myeloid leukemia. Annals of hematology 2014, 93 (6): 977-982.
[33]
Kao HW: Gene mutation patterns in patients with minimally differentiated acute myeloid leukemia. Neoplasia (New York, NY) 2014, 16 (6): 481-488.
[34]
Bachas C, Schuurhuis GJ, Reinhardt D, Creutzig U, Kwidama ZJ, Zwaan CM, van den Heuvel-Eibrink MM, De Bont E, Elitzur S, Rizzari C et al: Clinical relevance of molecular aberrations in paediatric acute myeloid leukaemia at first relapse. British journal of haematology 2014, 166 (6): 902-910.
[35]
Park MJ, Park SH, Park PW, Seo YH, Kim KH, Jeong JH, Kim M, Ahn JY, Lee JH, Park J et al: Frequency of KRAS mutations in adult Korean patients with acute myeloid leukemia. International journal of hematology 2013, 98 (5): 549-557.
[36]
Zuo Z, Medeiros LJ, Chen Z, Liu DS, Bueso-Ramos CE, Luthra R, Wang SA: Acute Myeloid Leukemia (AML) with Erythroid Predominance Exhibits Clinical and Molecular Characteristics that Differ from Other Types of AML. PloS one 2012, 7 (7).
[37]
Zebisch A, Wölfler A, Fried I, Wolf O, Lind K, Bodner C, Haller M, Drasche A, Pirkebner D, Matallanas D et al: Frequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemia. Leukemia 2012, 26 (8): 1842-1849.
[38]
Sano H, Shimada A, Taki T, Murata C, Park M, Sotomatsu M, Tabuchi K, Tawa A, Kobayashi R, Horibe K et al: RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group. International journal of hematology 2012, 95 (5): 509-515.
[39]
Ahmad EI, Gawish HH, Al Azizi NM, Elhefni AM: The prognostic impact of K-RAS mutations in adult acute myeloid leukemia patients treated with high-dose cytarabine. OncoTargets and therapy 2011, 4: 115-121.
[40]
Preston R, Däbritz J, Hänfler J, Oettle H: Mutational analysis of K-ras codon 12 in blood samples of patients with acute myeloid leukemia. Leukemia research 2010, 34 (7): 883-891.
[41]
Bachas C, Schuurhuis GJ, Hollink IH, Kwidama ZJ, Goemans BF, Zwaan CM, van den Heuvel-Eibrink MM, de Bont ES, Reinhardt D, Creutzig U et al: High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. Blood 2010, 116 (15): 2752-2758.
[42]
Ritter M, Kim TD, Lisske K, Thiede C, Schaich T, Neubauer A: Prognostic significance of N-RAS and K-RAS mutations in 232 patients with acute myelold leukemia. Haematologica 2004, 89 (11): 1397-1399.
[43]
Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, Asou N, Kuriyama K, Jinnai I, Shimazaki C et al: Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. In: Blood. vol. 93; 1999: 3074-3080.
[44]
DeMelo MB, LorandMetze I, Lima CSP, Saad STO, Costa FF: ''N-ras gene point mutations in Brazilian acute myelogenous leukemia patients correlate with a poor prognosis''. Leukemia & lymphoma 1997, 24 (3-4): 309-317.
[45]
Neubauer A, Dodge RK, George SL, Davey FR, Silver RT, Schiffer CA, Mayer RJ, Ball ED, Wurster-Hill D, Bloomfield CD et al: Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 1994, 83 (6): 1603-1611.
[46]
Paquette RL, Landaw EM, Pierre RV, Kahan J, Lubbert M, Lazcano O, Isaac G, McCormick F, Koeffler HP: N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 1993, 82 (2): 590-599.
[47]
Casey G, Rudzki Z, Roberts M, Hutchins C, Juttner C: N-ras mutation in acute myeloid leukemia: incidence, prognostic significance and value as a marker of minimal residual disease. Pathology 1993, 25 (1): 57-62.
[48]
Nakagawa T, Saitoh S, Imoto S, Itoh M, Tsutsumi M, Hikiji K, Nakamura H, Matozaki S, Ogawa R, Nakao Y et al: Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia. Oncology 1992, 49 (2): 114-122.
[49]
Radich JP, Kopecky KJ, Willman CL, Weick J, Head D, Appelbaum F, Collins SJ: N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. Blood 1990, 76 (4): 801-807.
[50]
Mulligan G, Lichter DI, Di Bacco A, Blakemore SJ, Berger A, Koenig E, Bernard H, Trepicchio W, Li B, Neuwirth R et al: Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood 2014, 123 (5): 632-639.
[51]
Parikh C, Subrahmanyam R, Ren R: Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice. Blood 2006, 108 (7): 2349-2357.
[52]
Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, Wong JC, Braun BS, Wolff L, Jacks T et al: Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood 2011, 117 (6): 2022-2032.
[53]
Cuiffo B, Ren R: Palmitoylation of oncogenic NRAS is essential for leukemogenesis. Blood 2010, 115 (17): 3598-3605.
[54]
Creutzig U, Zimmermann M, Reinhardt D, Rasche M, von Neuhoff C, Alpermann T, Dworzak M, Perglerova K, Zemanova Z, Tchinda J et al: Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. Cancer 2016.
[55]
Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D, Tidefelt U, Wahlin A, Hoglund M: Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009, 113 (18): 4179-4187.
[56]
Buchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Muller-Tidow C, Braess J, Spiekermann K, Kienast J, Staib P et al: Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009, 27 (1): 61-69.
[57]
Frohling S, Schlenk RF, Kayser S, Morhardt M, Benner A, Dohner K, Dohner H, German-Austrian AMLSG: Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 2006, 108 (10): 3280-3288.
[58]
Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE, Petersdorf SH: Age and acute myeloid leukemia. Blood 2006, 107 (9): 3481-3485.
Browse journals by subject